Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid–based proteasome inhibitors by Encouse B. Golden, Philip Y. Lam,

Slides:

Advertisements

Similar presentations

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,

Advertisements

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways.

What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance by Marta Palomo, Enrique Mir, Montse Rovira,

CD8 + T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia by Li Ma, Elisa Simpson,

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma by Salvia Jain, Dina Stroopinsky, Li Yin, Jacalyn Rosenblatt, Maroof Alam, Parul.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Formation of human hepatocytes by human hematopoietic stem cells in sheep by Graça Almeida-Porada, Christopher D. Porada, Jason Chamberlain, Ali Torabi,

Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells by Shannon A. Keller, Elaine J. Schattner, and Ethel Cesarman Blood.

Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B- cell lymphomas by Lingchen Fu, Yen-Chiu Lin-Lee,

Uncontrolled Wnt signaling causes leukemia

The beauty of TLR agonists for CTCL

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells by Changchun.

Do HSCs divide asymmetrically?

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

Dasatinib suppresses in vitro natural killer cell cytotoxicity

Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.

Defects in DBA: more than meets the eye

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,

Next-generation leukemia immunotherapy

An endothelial metronome breast cancer?

When monocyte life hangs by a thread

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma by Lotta.

Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to.

BTK inhibition in myeloma: targeting the seed and the soil

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

by Feng-Ting Liu, Samir G. Agrawal, Zanyar Movasaghi, Peter B

Transplants for the elderly in myeloma

How I treat elderly patients with myeloma

by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen

by Christina K. Ullrich, Jerome E. Groopman, and Ramesh K. Ganju

Skovseth et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood.

Shubhadeep Roychoudhury, Ashok Agarwal, Gurpriya Virk, Chak-Lam Cho

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Fluorescent neutrophils throw the spotlight on inflammation

by Peter L. Turecek, Hans Peter Schwarz, and Bernd R. Binder

by Rizwan Masood, Megan E

by Alexander Röth, Andreas Hüttmann, Russell P

Has the T cell bitten off more than it can chew?

A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of.

Whipping NF-κB to Submission via GADD45 and MKK7

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma by Kyle Runckel, Matthew J. Barth, Cory.

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd,

Annexin and APS: the clot thickens

Bortezomib sensitivity correlates with basal NF-κB activity in KP lung adenocarcinoma cell lines. Bortezomib sensitivity correlates with basal NF-κB activity.

Cytotoxic activities of polymer micelles containing CFZ in H460 (A) and select micelle formulations in RPMI-8226 (B) cell lines. Cytotoxic activities of.

Cytotoxic effects of PM1 and PM2 empty particle controls and coincubation of CFZ with empty particles tested in H460 (A) and RPMI-8226 (B) cells. Cytotoxic.

by Sondra Downey-Kopyscinski, Ellen W

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL by Kallesh D. Jayappa, Craig A.

Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells by Scott Best, Taylor Hashiguchi, Adam Kittai, Nur.

ROS induction and ATR inhibition synergize in inducing multiple myeloma (MM) cell death. ROS induction and ATR inhibition synergize in inducing multiple.

MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods by Mikhail Roshal, Juan A. Flores-Montero,

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

John Koreth, Edwin P. Alyea, William J. Murphy, Lisbeth A. Welniak

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

CD16 uses additional pathways for killing.

A, chemical structures of PRIMA-1 and PRIMA-1Met.

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.

Tipifarnib and bortezomib are synergistic in cytotoxicity assays

Inhibitions of the proteasome and aggresome pathways by bortezomib and DACi. Unfolded and/or misfolded proteins are targeted by ubiquitin for degradation.

Effect of IS on proliferation, senescence, and the production of NO and ROS from endothelial cells. Effect of IS on proliferation, senescence, and the.

Identification of compounds that enhance TMZ cytotoxicity in melanoma cells by screening the Spectrum Collection library. Identification of compounds that.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Presentation transcript:

Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid–based proteasome inhibitors by Encouse B. Golden, Philip Y. Lam, Adel Kardosh, Kevin J. Gaffney, Enrique Cadenas, Stan G. Louie, Nicos A. Petasis, Thomas C. Chen, and Axel H. Schönthal Blood Volume 113(23): June 4, 2009 ©2009 by American Society of Hematology

EGCG neutralizes the cytotoxic effects of BZM in multiple myeloma cells. Encouse B. Golden et al. Blood 2009;113: ©2009 by American Society of Hematology

EGCG neutralizes the cytotoxic effects of BZM in glioblastoma. Encouse B. Golden et al. Blood 2009;113: ©2009 by American Society of Hematology

Complete green tea extract and its polyphenols EGC, ECG, and EC neutralize the cytotoxic effects of BZM. (A) Chemical structures of the green tea polyphenols EGC, ECG, and EC. (B) Percentage cell viability of LN229 cells treated for 48 hours with increasing... Encouse B. Golden et al. Blood 2009;113: ©2009 by American Society of Hematology

EGCG neutralizes the cytotoxic effect of MG-262 and proteasome inhibitor IX but not NFV, MG- 132, and proteasome inhibitor I. (A) Chemical structures of the proteasome inhibitors NFV, proteasome inhibitor I (PS-I), MG-132, MG-262, and proteasome inhibitor IX... Encouse B. Golden et al. Blood 2009;113: ©2009 by American Society of Hematology

EGCG prevents proteasome inhibition and ER stress induction when combined with BZM and MG-262, but not MG-132. Encouse B. Golden et al. Blood 2009;113: ©2009 by American Society of Hematology

EGCG neutralizes the antitumoral effects of BZM in multiple myeloma in vivo. Encouse B. Golden et al. Blood 2009;113: ©2009 by American Society of Hematology

BZM does not generate ROS, but directly reacts with EGCG to form a new boronate product. Encouse B. Golden et al. Blood 2009;113: ©2009 by American Society of Hematology